Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

6.620 +0.100 (+1.53%)
Streaming Delayed Price Updated: 9:46 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,630
Open 6.510
Bid (Size) 6.620 (2)
Ask (Size) 6.650 (3)
Prev. Close 6.520
Today's Range 6.500 - 6.740
52wk Range 5.700 - 13.32
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets

Performance

YTD
-44.16%
-44.16%
1 Month
-17.46%
-17.46%
3 Month
-30.61%
-30.61%
6 Month
+0.30%
+0.30%
1 Year
-42.13%
-42.13%

More News

Read More
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Relay Therapeutics: Q4 Earnings Insights
Via Benzinga
Relay Therapeutics's Earnings: A Preview
Via Benzinga
AI Surge Ending: Only One Category Was Up This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
The 7 Best Penny Stocks for 200% Returns
Via InvestorPlace
Earnings Scheduled For February 22, 2024
Via Benzinga
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces $30 Million Private Placement Financing
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Index Up 26% In December
Via Talk Markets
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Relay Therapeutics: Here's What You Need To Know
Via Benzinga
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Unlocking AI investment opportunities in healthcare
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.